Eliminating solid tumors with AI-driven, multiplex gene-edited CAR-T cells

Advancing cell therapies that break through immunosuppressive tumor barriers, enabling effective and durable cancer control

About

Our Support

KiraGen Bio is proud to join the 2048 Ventures Biotech Studio, marking a pivotal step in our quest to innovate CAR-T therapies for solid tumors. This recognition fuels our journey with vital resources and expert networks, accelerating our path to transforming cancer treatment.

Recognitions

Harvard Undergraduate Capital Partners Innovation

Harvard Consulting Business and the Environment

HUCP Innovation Fund x CBE Ventures Competition

Finalists in the 2023 Harvard Undergraduate Capital Partners Innovation Fund x Consulting, Business, the Environment Venture Competition

Nucleate Activator Program

Finalists in the 2024 Nucleate Activator Program final pitch showcase in Boston

Presidents Innovation Challenge

Semi-finalists in the 2024 Harvard iLab's President's Innovation Challenge

Finalists in the 2024 M2D2 $200k Grand Challenge

Co-founder and CEO, Aaron Edwards selected to be a Termeer Fellow, a values-driven leadership program for first time biotech founder/CEOs

Co-founder and CSO, Ryan Murray selected to be in 5050 Program, helping foster deep tech scientists/engineers become great founders.

Science

Redefining CAR-T with a differentiated approach:

AI-driven design and multiplex gene editing for superior efficacy against solid tumors.

Our Science

AI-Driven Design

Leveraging machine learning to pinpoint optimal gene editing combinations, enhancing CAR-T cell efficacy against solid tumors.

Multiplex Gene Editing

Employing cutting-edge technology to simultaneously edit 8+ genes, setting a new standard in cell therapy engineering.

Allogeneic CAR-T

Our allogeneic CAR-T cells are engineered to maintain efficacy against immunosuppressive solid tumor microenvironment.

Team

Meet the Team

Co-Founder, CEO

Aaron Edwards, MSc, MS/MBA ('24)

Aaron Edwards, an MS/MBA Biotechnology candidate at Harvard Business School, has led innovative cell and gene therapy projects across prominent biotech companies. At bluebird bio, he spearheaded early programs developing gene-edited immunotherapies including both CAR-T and TCR-T. He then served as the in vitro biology lead for Beam Therapeutics’ BEAM-201, now a clinical stage asset. His experience also includes driving advancements at Eli Lilly, 1910 Genetics, BioMarin and Rejuvenate Bio. As CEO of KiraGen, Aaron leverages his acute blend of hands-on cell engineering expertise and business acumen to propel the next generation of genetic medicines.

KiraGen Bio Co-Founder and CSO, Ryan Murray

Co-Founder, CSO

Ryan Murray, PhD ('24)

Ryan Murray, a PhD candidate at Northeastern University, leads innovative research to unlock the potential of CAR-T cell therapy for solid tumors using cutting-edge gene editing. At bluebird bio, he pioneered synthetic biology strategies to enhance engineered T cell products. His significant contributions further include leading early development efforts for Beam’s oncology IND BEAM-201 and spearheading high-impact initiatives like Fifty 50 Bio x Climate and Nucleate. As CSO at KiraGen, Ryan leverages his sharp expertise across key areas in engineered cell therapy to propel the next generation of genetic medicines